<DOC>
	<DOCNO>NCT02228213</DOCNO>
	<brief_summary>The purpose study determine whether MIS416 administer weekly 12 month safe , tolerable , improve range sign symptom associate secondary progressive multiple sclerosis .</brief_summary>
	<brief_title>Safety Efficacy Study MIS416 Treat Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description>The primary objective study : 1 . Determine efficacy MIS416 , relative placebo , administer repeatedly via weekly intravenous ( IV ) administration subject Secondary Progressive Multiple Sclerosis , assess effect measure neuromuscular function . 2 . Determine safety tolerability weekly regimen MIS416 . The secondary objective study : 1 . Determine effect MIS416 disease activity neurodegeneration assess change Magnetic Resonance Imaging ( MRI ) marker include lesion , whole brain atrophy ( WBA ) Magnetization Transfer Ratio ( MTR ) . 2 . Determine effect MIS416 Patient Reported Outcomes ( PRO ) relate disability health status . 3 . Assess , subset subject , pharmacodynamic ( PD ) effect MIS416 , include effect serum , Peripheral Blood Mononuclear Cell ( PBMC ) , Cerebral Spinal Fluid ( CSF ) cytokine/chemokine level expression pattern .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>1 . A historical current cranial MRI scan demonstrating T2hyperintense lesion consistent MS. 2 . Has SPMS determine 2010 Update McDonald Criteria 3 . An Expanded Disability Status Scale ( EDSS ) 3.0 6.5 Screening . 4 . Has SPMS , judgment investigator , clinically active functionally progressive within 2 year prior Screening 5 . The absence MS relapse least two year prior Baseline . 6 . Neurologically stable least four week prior Screening . 7 . Has follow laboratory value within three day prior initiation Investigational Product : Absolute neutrophil count ( ANC ) &gt; = 1 x 109/L ; Platelet count &gt; = 100 x 109/L ; Serum creatinine = &lt; 1.5 mg/dL ; Aspartate aminotransferase ( AST ) = &lt; 2 × upper limit normal ; Alanine aminotransferase ( ALT ) = &lt; 2 × upper limit normal . 8 . Provided write informed consent participate . 1 . Has primary Progressive MS ( PPMS ) , Relapsing Remitting ( RRMS ) , progressive relapse MS determine 2010 update McDonald Criteria . 2 . Has complete discontinuation period approve and/or investigational multiple sclerosis disease modify therapy prior screen . 3 . Has immunomodulatory drug therapy immunosuppressive therapy within four week prior Screening , systemic corticosteroid within eight week prior Screening . 4 . Any previous exposure investigational MS therapeutic vaccine . 5 . Any use celldepleting monoclonal antibody include , limited , Rituximab , Ocrelizumab . 6 . A diagnosis history collagen vascular disease ( include Sjögren 's syndrome systemic lupus erythematosus ) , anticardiolipin antibody syndrome , cerebral autosomal dominant arteriopathy subcortical infarct leukoencephalopathy , sarcoidosis , vasculitis , Behcet 's syndrome and/or Lyme disease . 7 . Contraindication MRI ( e.g. , pacemaker contraindicate implanted metal device , allergy gadolinium , unmanageable claustrophobia ) . 8 . A history alcohol drug abuse ( include cannabinoid use ) within two year prior Screening . 9 . Has major surgery radiation therapy within four week prior Screening . 10 . Has active infection require antibiotic within two week prior Screening . 11 . Has active malignancy within two year Screening , exception basal cell carcinoma squamous cell carcinoma skin . 12 . Uncontrolled congestive heart failure , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack within twelve week prior Screening . 13 . Has angina , symptomatic coronary artery disease , know cardiomyopathy . 14 . Has symptomatic cardiac dysrhythmias require treatment , persistent prolongation QTcF ( Fredericia ) interval &gt; 450 msec male &gt; 470 msec female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>SPMS</keyword>
</DOC>